Based on the Tourmaline Bio Inc. stock forecast from 5 analysts, the average analyst target price for Tourmaline Bio Inc. is USD 46.78 over the next 12 months. Tourmaline Bio Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tourmaline Bio Inc. is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Tourmaline Bio Inc.’s stock price was USD 15.10. Tourmaline Bio Inc.’s stock price has changed by -7.36% over the past week, +15.27% over the past month and +4.14% over the last year.
No recent analyst target price found for Tourmaline Bio Inc.
No recent average analyst rating found for Tourmaline Bio Inc.
Company Overview Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Read Less
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cy...Read More
Frequently Asked Questions About Tourmaline Bio Inc. (TRML) Stock
Based on ratings from 5 analysts Tourmaline Bio Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRML's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for TRML is USD 46.78 over the next 12 months. The maximum analyst target price is USD 63 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on TRML's stock to indicate if its overvalued.
The last closing price of TRML's stock was USD 15.10.
The most recent market capitalization for TRML is USD 0.33B.
Based on targets from 5 analysts, the average taret price for TRML is projected at USD 46.78 over the next 12 months.
This means that TRML's stock price may go up by +209.79% over the next 12 months.
We can't find any ETFs which contains Tourmaline Bio Inc.'s stock.
As per our most recent records Tourmaline Bio Inc. has 74 Employees.
Tourmaline Bio Inc.'s registered address is 27 West 24th Street, New York, NY, United States, 10010.
You can get more information about it from Tourmaline Bio Inc.'s website at https://www.tourmalinebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Tourmaline Bio Inc. (TRML) Stock
Based on ratings from 5 analysts Tourmaline Bio Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRML's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for TRML is USD 46.78 over the next 12 months. The maximum analyst target price is USD 63 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on TRML's stock to indicate if its overvalued.
The last closing price of TRML's stock was USD 15.10.
The most recent market capitalization for TRML is USD 0.33B.
Based on targets from 5 analysts, the average taret price for TRML is projected at USD 46.78 over the next 12 months.
This means that TRML's stock price may go up by +209.79% over the next 12 months.
We can't find any ETFs which contains Tourmaline Bio Inc.'s stock.
As per our most recent records Tourmaline Bio Inc. has 74 Employees.
Tourmaline Bio Inc.'s registered address is 27 West 24th Street, New York, NY, United States, 10010.
You can get more information about it from Tourmaline Bio Inc.'s website at https://www.tourmalinebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRML !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
